Search results
Results from the WOW.Com Content Network
Richardson is a professor of emergency medicine, health evidence, and policy at Icahn School of Medicine at Mount Sinai. She is the Vice Chair for Academic, Research and Community Programs of the Department of Emergency Medicine at Icahn. [1]
In 1979, Bederson graduated Phi Beta Kappa from Cornell University, where he was the Ivy League Gymnastics All-Around Champion for three years.He earned his M.D. at the University of California, San Francisco in 1984, taking a year off to study sculpture in the master's degree program at New York University and hold a solo art show in New York City.
Dr. H. Richard Winn is an American neurosurgeon, and professor of neurosurgery and neuroscience at Mount Sinai School of Medicine.Winn was chairman of neurological surgery at the University of Washington School of Medicine from 1983 to 2002.
A new survey found that 1 in 5 adults “who say they have no personal or family history of heart attack or stroke,” reported “routinely” taking a low-dose aspirin
In 1963 The Mount Sinai Hospital chartered The Mount Sinai School of Medicine, the first medical school to grow out of a non-university in more than 50 years. [6] The school opened to students in 1968 and in 2012 changed its name to Icahn School of Medicine at Mount Sinai. [ 9 ]
David L. Reich (born February 7, 1960) is an American academic anesthesiologist, who has been President & Chief Operating Officer of The Mount Sinai Hospital, and President of Mount Sinai Queens (both part of the Mount Sinai Health System in New York City), since October 2013.
She is also a professor of medicine and pediatrics at Mount Sinai School of Medicine and a member of the Immunology institute. [5] She is the director of the Immunodeficiency Clinic at Mount Sinai, where she treats patients with primary immunodeficiency disorders. [1] She also does important drug research related to immunodeficiency disorders. [1]
Dr. Robert S. Rosenson studies the effects of lipid-lowering therapy in different regions of the United States. [5] He researches selective inhibitors of inflammatory pathways such as lipoprotein-associated with phospholipase A2, [6] and also did research on the efficacy and safety of evolocumab in patients with type 2 diabetes mellitus and hypercholesterolemia.